SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: djmurdock
Search This Board: 
Last Post: 3/23/2017 4:12:29 PM - Followers: 47 - Board type: Free - Posts Today: 0

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.

Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.

Extremely low float:


A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ZYNE News: Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry 03/16/2017 09:30:00 AM
ZYNE News: Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth 03/15/2017 09:30:00 AM
ZYNE News: Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017 03/13/2017 07:35:00 AM
ZYNE News: Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoar... 03/13/2017 07:30:00 AM
ZYNE News: Current Report Filing (8-k) 03/13/2017 07:21:49 AM
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#533   Closed one cent above pervious high 4 days a surfer 03/23/17 04:12:29 PM
#532   IPO today? a surfer 03/23/17 04:11:01 PM
#531   ZYNE market cap 260 million. Similar company TRPX excboe 03/23/17 12:11:48 PM
#530   Beautiful day! a surfer 03/23/17 11:29:29 AM
#529   Bout time ZYNE -This chart is amazingly predictable. surfgreen 03/23/17 11:04:06 AM
#528   :-) $ZYNE Cbdpotential 03/22/17 10:54:35 PM
#527   Zynerba's transdermal approach has significant benefits djmurdock 03/22/17 09:54:01 PM
#526   Awesome new presentation!!! djmurdock 03/22/17 09:48:08 PM
#525   More WolfOfGrnStreet 03/21/17 12:33:01 AM
#524   22$+ Cbdpotential 03/20/17 10:19:29 AM
#523   Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth Source Cbdpotential 03/15/17 09:29:32 AM
#522   Great news !!! djmurdock 03/14/17 02:10:45 AM
#521 djmurdock 03/14/17 02:09:49 AM
#520   Strong close! Wish my other stocks we're doing djmurdock 03/08/17 04:20:50 PM
#519   Out of the weekly cloud Catalysts coming Support holding Quokkie 03/02/17 06:55:06 PM
#518   Looks like we are hitting stubborn resistance at Gpheart2016 03/02/17 12:03:24 PM
#517   Record shorts Anticipated positive earnings Hold on tight. Quokkie 03/01/17 09:30:38 AM
#516   Report seems conservative in $30s. biotechnician 02/28/17 02:37:44 PM
#515   Monster stock! $ZYNE Cbdpotential 02/27/17 04:37:41 PM
#514 Medical mj safe Quokkie 02/25/17 02:22:09 AM
#513   Yeah, I see that too. Normally the Triple9 02/24/17 11:05:28 PM
#512   This is what Etrade is reporting as the jim992 02/24/17 10:45:53 PM
#511   Honestky I think this is a great set up Cbdpotential 02/24/17 03:21:47 PM
#510   Now your talking! :) djmurdock 02/24/17 03:20:01 PM
#509   funny dip a surfer 02/24/17 03:01:38 PM
#508   Not sure why I said eoy I meant to Cbdpotential 02/24/17 02:07:04 PM
#507   Another great day, while the whole sector is djmurdock 02/24/17 01:13:08 PM
#506   BOOM! Maxim Group Initiates Coverage On Zynerba Triple9 02/24/17 01:05:42 PM
#505   $ZYNE$ Emerging leader in synthetic cannabis technology. Amazing surfgreen 02/24/17 11:32:10 AM
#504   That speaks volumes imo I'm growing weary of Quokkie 02/24/17 10:15:21 AM
#503   Sector leader! Lots of red out there a surfer 02/24/17 10:10:06 AM
#502   Same thing here...trying to reenter low 22's now... CoachMarc 02/24/17 09:30:15 AM
#501   Oh darn, I've been taking profits on this Triple9 02/23/17 11:58:57 PM
#500   Headed to 30$ by eoy imo Cbdpotential 02/23/17 11:43:00 PM
#499   Nice AH :-D Go $ZYNE Cbdpotential 02/23/17 11:42:20 PM
#496   Setting up beautifullly for new highs. a surfer 02/22/17 09:33:16 PM
#495   Another strong day! Holding tight. djmurdock 02/22/17 10:28:18 AM
#494   Great sign there my friend. We do not WolfOfGrnStreet 02/21/17 10:57:27 PM
#493   More institutional buying djmurdock 02/21/17 01:52:46 PM
#492   Thanks a ton--I always learn something when you Pugetsounder1 02/20/17 11:43:52 AM
#490   To be approved as an index tracking fund Triple9 02/19/17 11:30:31 PM
#489   T9, how do u think the ETF will Pugetsounder1 02/19/17 10:56:28 PM
#487   Representatives Dana Rohrabacher (CA-48), Earl Blumenauer (OR-03), Don Triple9 02/16/17 08:02:12 PM
#486   Did you know there's a MMJ Index called Triple9 02/16/17 05:32:18 PM
#485   Can't stop the $zyne train! Chuga chuga chuga djmurdock 02/16/17 02:42:17 PM
#484   GREEN! What a comeback! Roaring ZYNE! CoachMarc 02/16/17 02:04:14 PM
#483   A green close today would be very bullish. djmurdock 02/16/17 01:14:32 PM
#482   No sure what the close will be like, CoachMarc 02/16/17 01:06:46 PM
#481 djmurdock 02/16/17 02:22:12 AM
#480   It's anyone's guess but it is very strong. WolfOfGrnStreet 02/15/17 08:36:46 PM